

藥學相關資料庫的選擇與應用

義大醫療財團法人義大醫院

藥劑部 黃佳真藥師

2012/7/14 (六)

普及率最高的藥物資料庫

MICROMEDEX® 2.0

▶ 點閱率排行榜

資料庫 電子期刊 電子書 網路資源 個人化服務

資源瀏覽

- 中日文資料庫
- 西文資料庫
- 實證醫學
- 題名排列
- 類型排列
- 出版商排列
- 語文別排列
- 試用資源
- 免費資源
- 新到資料庫
- 熱門點閱**
- 熱門收藏
- 熱門推薦

【資源查詢】

☐ 精確檢索

近30天熱門點閱：

共 **50** 筆

 每頁筆數
 第 筆

編號	題名	類型	主題	出版商(社)	收錄年代	Embargo	其它註記	Web2.0
1	UpToDate實證醫學資料庫 +收藏 ★推薦 !簡介	①	Medicine醫學	UpToDate			問題通報	點閱 ：2509 收藏 ：54 ★推薦 ：12
2	PubMed +收藏 ★推薦 !簡介	①	Medicine醫學	NCBI			問題通報 Free	點閱 ：2506 收藏 ：68 ★推薦 ：6
3	Airiti Library 華藝線上圖書館(中文電子期刊服務CEPS) +收藏 ★推薦 !簡介	①	Integrated Subject綜合學科	華藝			問題通報	點閱 ：2856 收藏 ：39 ★推薦 ：7
4	MICROMEDEX 2.0 (MICROMEDEX Healthcare Series) +收藏 ★推薦 !簡介	①	Pharmacology藥理學	碩睿資訊			問題通報	點閱 ：1059 收藏 ：33 ★推薦 ：5

機構所訂購的子資料庫內容

我的訂閱 | MICROMEDEX 開道 | 登出 | 說明

MICROMEDEX® 訂閱
用於 E-Da Hospital (客戶號: 749070001)

Your Subscribed Products

MICROMEDEX 2.0

- Alternative Medicine
- DRUGDEX® System
- Imprint Codes in Identidex®
- Interaction Checking
- IV Compatibility
- MARTINDALE
- PDR®

Non-subscribed Products

MICROMEDEX 2.0

- AAPCC Codes in POISINDEX®
- Detailed Drug Information for the Consumer
- DISEASEDEX™ Emergency Medicine
- DISEASEDEX™ General Medicine
- Index Nominum
- Italian Drug Database
- Lab Advisor™
- MSDS from USP
- P&T QUIK® Reports
- PharmacyXpert
- POISINDEX® Managements
- POISINDEX® System
- RED BOOK Online®
- REPRORISK® System

列印 關閉

藥物
相互作用

Diabetes mellitus

360° 檢視儀錶板 | 跳轉

MICROMEDEX 疾病綜述

- Definition
- Ongoing Assessment

檢視綜述文件 ▶

Diabetes mellitus 同時在以下

- ▶ Drug Information (1)
- ▶ Drug Consults (5)
- ▶ Toxicology (17)

基本藥物資訊查詢

以Dronedarone為例
使用劑量與注意事項？

工具: 藥物相互作用 | Trissel's™2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | 計算器 | CareNotes®

Dronedarone

SEARCH

範例搜尋

Dronedarone Hydrochloride [Your search: Dronedarone]

Oral

360° 檢視儀錶板 | [跳轉到 413 其他搜尋結果](#)

MICROMEDEX 藥物綜述資訊

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Black Box Warning
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Toxicology - Clinical Effects
- Toxicology - Treatment
- Toxicology - Range of Toxicity
- Clinical Teaching
- References

[檢視綜述文件 ▶](#) | [檢視詳細文件 ▶](#)

其他資訊

MARTINDALE

- Dronedarone

藥物工具

DRUG SAFETY AND AVAILABILITY

- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

PRODUCT LOOKUP

- Tox & Drug: Dronedarone Hydrochloride
- Martindale: Dronedarone Hydrochloride

DRUG CONSULTS (3 結果)

- ATRIAL FIBRILLATION - DRUG TREATMENT GUIDELINES
- NEW DRUG APPROVALS - 2009 MICROMEDEX NEWS
- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

COMPARATIVE EFFICACY (1 結果)

- Amiodarone Hydrochloride

MARTINDALE - 其他資訊 (1 結果)

Dosing & Indications

DOSING & INDICATIONS

Adult Dosing
Pediatric Dosing
Dose Adjustments
FDA-Labeled Indications
Non-FDA Labeled Indications

BLACK BOX WARNING

CONTRAINDICATIONS/WARNINGS

Contraindications
Precautions
Pregnancy Category
Breast Feeding

DRUG INTERACTIONS (SINGLE)

ADVERSE EFFECTS

Common
Serious

NAME INFO

US Trade Name
Class
Regulatory
Generic

MECHANISM OF ACTION/P

ADMINISTRATION

HOW SUPPLIED

TOXICOLOGY

Clinical Effects
Treatment

Dronedarone Hydrochloride

DrugPoint® 綜述 ⓘ
其他來源 >

DOSING & INDICATIONS

+ 全部展開
- 全部折疊
↑ 頁首

Adult Dosing

檢視 DRUGDEX 中的詳細資訊 ▶

- strong CYP3A4 inhibitors (eg, ketoconazole) and Class I or III antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) must be discontinued prior to initiating dronedarone hydrochloride [1]
- Atrial fibrillation, Paroxysmal or Persistent: 400 mg ORALLY twice daily with morning and evening meals [1]

Pediatric Dosing

1. Dronedarone不可與CYP3A4 強效抑制劑併用
2. 使用 dronedarone 前必需停用第一類和第三類抗心律不整藥物
3. 陣發性(paroxysmal) OR 持續性(persistent) AF: 400mg BID

Dosing & Indications

OVERVIEW

DOSING INFORMATION

Drug Properties
Storage and Stability
Adult Dosage
Pediatric Dosage

PHARMACOKINETICS

Drug Concentration Levels
ADME

CAUTIONS

Black Box Warning
Contraindications
Precautions
Adverse Reactions
Teratogenicity/Effects in
Pregnancy/Breastfeeding
Drug Interactions

CLINICAL APPLICATIONS

Monitoring Parameters
Patient Instructions
Place In Therapy
Mechanism of Action / Pharmacology
Therapeutic Uses
Comparative Efficacy / Evaluation With
Other Therapies

REFERENCES

DRONEDARONE

DRUGDEX® 評價

其他來源

DOSING INFORMATION

Adult Dosage

Normal Dosage
Dosage in Renal Failure
Dosage in Hepatic Insufficiency

Normal Dosage

Important Note

Dronedaron Hydrochloride

Important Note

) Strong CYP3A4 inhibitors (eg, ketoconazole) and Class I or III antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) must be discontinued prior to initiating dronedarone hydrochloride [1].

Dronedaron Hydrochloride

Oral route

Atrial fibrillation, Paroxysmal or Persistent

1) To reduce the risk of hospitalization due to atrial fibrillation (AF) for patients in sinus rhythm who have a history of paroxysmal or persistent atrial fibrillation, the recommended dosage of dronedarone hydrochloride is 400 milligrams orally twice daily with the morning and the evening meal [3].

Dosage in Renal Failure

A) Dronedaron Hydrochloride

1) No dronedarone hydrochloride dosage adjustment is recommended in patients with renal impairment [3]

顯示整個文件 | 列印

全部展開 | 全部折疊 | 頁

Monitoring Parameters

OVERVIEW

DOSING INFORMATION

PHARMACOKINETICS

CAUTIONS

CLINICAL APPLICATIONS

REFERENCES

DRONEDARONE

DRUGDEX® 評價

其他來源

CLINICAL APPLICATIONS

Monitoring Parameters

1

2

A) Dronedarone Hydrochloride

1) Therapeutic

a) Physical Findings

1) Monitor ECG for normalized sinus rhythm.

2) Toxic

a) Laboratory Parameters

1) Monitor hepatic function, periodically, especially during the first 6 months of therapy [8].

2) Monitor renal function periodically during therapy [8].

b) Physical Findings

1) Monitor ECG for QTc (Bazett) interval prolongation not greater than or equal to 500 milliseconds.

Patient Instructions

Place In Therapy

Mechanism of Action / Pharmacology

Therapeutic Uses

顯示整個文件

列印

全部展開

全部折疊

頁

竇性心律

特別是在治療期的第6個月監測肝功能

治療期間定期監測腎功能

QT間距<500毫秒

Comparative Efficacy / Evaluation With Other Therapies

OVERVIEW

DOSING INFORMATION

Drug Properties
Storage and Stability
Adult Dosage
Pediatric Dosage

PHARMACOKINETICS

Drug Concentration Levels
ADME

CAUTIONS

Black Box Warning
Contraindications
Precautions
Adverse Reactions
Teratogenicity/Effects in
Pregnancy/Breastfeeding
Drug Interactions

CLINICAL APPLICATIONS

Monitoring Parameters
Patient Instructions
Place In Therapy
Mechanism of Action / Pharmacology
Therapeutic Uses
Comparative Efficacy / Evaluation With
Other Therapies

REFERENCES

DRONEDARONE

DRUGDEX® 評價  其他來源 

CLINICAL APPLICATIONS

 全部展開 |  全部折疊 |  頁

▶ Mechanism of Action / Pharmacology

▶ Therapeutic Uses

▼ Comparative Efficacy / Evaluation With Other Therapies

Amiodarone Hydrochloride

Atrial fibrillation

a) Amiodarone was more effective than dronedarone to prevent the recurrence of atrial fibrillation (AF) but dronedarone may have a better safety profile in the Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Dronedarone Versus Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF (DIONYSUS). Patients (n=504; mean age, 64 +/- 10.7 years) with documented AF for more than 72 hours with an

DIONYSOS Study

唯一一個與 **amiodarone** 進行直接比較的研究

hypertension (66.9%), while 21.6% had congestive heart failure, and 16.5% had lone AF. Most patients had persistent AF (62.9%), while 21.6% were in their first episode. Patients in the

Mechanism of Action / Pharmacology

Therapeutic Uses

Comparative Efficacy / Evaluation With Other Therapies

Amiodarone Hydrochloride

Atrial fibrillation

a) Amiodarone was more effective than dronedarone to prevent the recurrence of atrial fibrillation (AF) but dronedarone may have a better safety profile in the Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Dronedarone Versus Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF (DIONYSOS). Patients (n=504; mean age, 64 +/- 10.7 years) with documented AF for more than 72 hours with an indication for cardioversion and antiarrhythmic treatment, and who were receiving oral anticoagulation, were randomized to receive dronedarone 400 mg orally twice daily (n=249) or amiodarone 600 mg orally daily for 28 days followed by 200 mg orally daily (n=255), for at least 6 months. If conversion to normal sinus rhythm did

?

1. DIONYSOS Study是唯一一個與 amiodarone 進行直接比較的研究 (RCT)、不曾使用過 amiodarone 之持續性心房纖維顫動患者隨機分配至400 mg 每日二次 dronedarone 組與 amiodarone 組 (前28天每日一次 amiodarone 600 mg，之後200 mg 每日一次)，各納入249人與255人，
2. 平均治療期間為7個月，在追蹤12個月減少心房纖維顫動復發方面 amiodarone 優於 dronedarone (42% vs. 63.5%)，成功心律復整 (cardioversion) 後再次復發方面 amiodarone 亦比 dronedarone 少 (24.3% vs. 36.5%)；但 dronedarone 組的提早停藥比例較 amiodarone 少 (10.4% vs. 13.3%)
3. 在 DIONYSOS Study中，amiodarone 在降低心房纖維顫動復發效果優於 dronedarone，dronedarone 在甲狀腺和神經方面安全性較高(但 dronedarone 胃腸副作用則多於 amiodarone)。

DRONEDARONE

DRUGDEX® 評價 

其他來源 ▶

CLINICAL APPLICATIONS

p=0.0311). The median duration of treatment with study drug was 12 months (range 0-36 months). After 12 months of treatment, the composite primary endpoint (recurrence of AF or premature drug discontinuation due to lack of efficacy or premature drug discontinuation due to intolerance) was significantly lower in the dronedarone arm (75.1%) versus the amiodarone arm (58.8%; hazard ratio (HR) 0.48 (95% CI 0.33-0.69), p=0.0001).

REFERENCES

[42] Le Heuzey JY, De Ferrari GM, Radzik D, et al: A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21(6):597-605.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

可連結文章全文

Drug Comparison Results

修改比較

查詢兩種藥物的完整比較

在欄中顯示 1

Amiodarone HCl

在欄中顯示 2

Dronedarone Hydrochloride

更新

跳轉到：[★ 頁首](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Amiodarone Hydrochloride

[Amiodarone HCl]

檢視 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

檢視 DRUGDEX 中的詳細資訊

- Advanced cardiac life support: 300 mg IV/INTRAOSSEOUSLY by rapid infusion; a single-dose of 150 mg IV/INTRAOSSEOUSLY may be repeated [2]
- Supraventricular arrhythmia: initial, 600 to 1200 mg ORALLY daily for 1 to 2 wks, tapered to 400 to 600 mg ORALLY daily for 1 to 3 wks, tapered to the lowest possible maintenance dose
- Supraventricular arrhythmia: maintenance, 200 mg ORALLY daily
- Supraventricular arrhythmia: IV/ORAL regimen; 300 mg IV for 1 hr, then 20 mg/kg for 24 hrs, then 600 mg ORALLY daily for 1 wk, then 400 mg ORALLY daily

Dronedarone Hydrochloride

檢視 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

檢視 DRUGDEX 中的詳細資訊

- strong CYP3A4 inhibitors (eg, ketoconazole) and Class I or III antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) must be discontinued prior to initiating dronedarone hydrochloride [1]
- Atrial fibrillation, Paroxysmal or Persistent: 400 mg ORALLY twice daily with morning and evening meals [1]

工具: 藥物相互作用 | Trissel's™ 2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | 計算器 | CareNotes®

SEARCH

範例搜尋

可用途徑 ▼

Dronedarone Hydrochloride

Dronedarone Hydrochloride

Oral

360° 檢視儀錶板 | ⬇ 跳轉到 413 其他搜尋結果

MICROMEDEX 藥物綜述資訊

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Black Box Warning
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Toxicology - Clinical Effects
- Toxicology - Treatment
- Toxicology - Range of Toxicity
- Clinical Teaching
- References

[檢視綜述文件 ▶](#) | [檢視詳細文件 ▶](#)

其他資訊

MARTINDALE

- Dronedarone

藥物工具

風險評估與風險管理 (Risk Evaluation and Mitigation Strategy; REMS)

安全性監測

DRUG SAFETY AND AVAILABILITY

- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

PRODUCT LOOKUP

- Tox & Drug: Dronedarone Hydrochloride
- Martindale: Dronedarone Hydrochloride

DRUG CONSULTS (3 結果)

- ATRIAL FIBRILLATION - DRUG TREATMENT GUIDELINES
- NEW DRUG APPROVALS - 2009 MICROMEDEX NEWS
- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

COMPARATIVE EFFICACY (1 結果)

- Amiodarone Hydrochloride

MARTINDALE - 其他資訊 (1 結果)



RESPONSE

提醒醫師處方前要再次評估利益與風險

The Food and Drug Administration Amendments Act of 2007 (FDAAA) gave FDA the authority to require Risk Evaluation and Mitigation Strategies (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A REMS may contain:

- A timetable for submission of assessments at 18 months, 3 and 7 years after the date of REMS approval is required.

- Any or all of the Additional Potential Elements:

病人用藥須知

降低嚴重風險

教育宣導計畫

- Medication guide
- Patient package insert that may reduce a serious risk of the drug
- Communication plan targeted to health care providers

- Elements to ensure safe use (ETASU) may be required when the above Additional Potential Elements are not sufficient to reduce the serious risks associated with the drug. The ETASU may include:

確保安全使用要件

- Certification of prescribers
- Certification of dispensers
- Dispensing limited to certain healthcare settings, such as a hospital
- Dispensing to patients with evidence of safe use, such as laboratory test results
- Specific patient monitoring requirements
- Patient registry enrollment

- Implementation system may be required to monitor and evaluate the implementation of the REMS ETASU and to improve the implementation of these elements.

執行系統-追蹤執行成效

Distribution Requirements of Providing Medication Guides

- Inpatient

RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

藥物諮詢 

- Inpatient
 - Patient or patient's agent receives
 - Drug is subject to an ETASU
- Outpatient when a healthcare pro
 - Patient or patient's agent receives
 - At time of first dispensing
 - When Medication Guide con
 - Drug is subject to an ETASU
- Outpatient when dispensed dire
 - Patient or patient's agent receives
 - Each time the drug is disper

參考：

1. U.S. Food and Drug Administration (FDA): Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration (FDA). Silver Spring, MD. 2011. Available from URL: <http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm> . As accessed 2011-12-12.

列印  關閉 

[1]

- A list of drugs with the FDA app
 - <http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm>
- A list of Medication Guides is av
 - <http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm>

Reference

1. U.S. Food and Drug Administration (FDA): Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies

FDA於2011/12/19發佈安全警訊



U.S. Food and Drug Administration

Protecting and Promoting *Your* Health

[A to Z Index](#) | [Follow FDA](#) | [FDA Voice Blog](#)

SEARCH

[Home](#) [Food](#) [Drugs](#) [Medical Devices](#) [Vaccines, Blood & Biologics](#) [Animal & Veterinary](#)

Drugs

[Home](#) [Drugs](#) [Drug Safety and Availability](#)

Drug Safety and Availability

[Drug Alerts and Statements](#)

[Importing Prescription Drugs](#)

[Medication Guides](#)

[Drug Safety Communications](#)

[Drug Shortages](#)

[Postmarket Drug Safety Information for Patients and Providers](#)

[Information by Drug Class](#)

[Medication Errors](#)

[FDA Drug Safety Newsletter](#)

[Drug Safety Podcasts](#)

[Safe Use Initiative](#)

FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events

This information has been updated in FDA Drug Safety Communication: Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events 12/19/2011.

Safety Announcement

[Additional Information for Patients](#)

[Additional Information for Healthcare Professionals](#)

[Data Summary](#)

Safety Announcement

[07-21-2011] The U.S. Food and Drug Administration (FDA) is reviewing data from a clinical trial that was evaluating the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with **permanent** atrial fibrillation. The study was stopped early after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo. Currently Multaq is approved for use in a different, but related patient population (see Facts about Multaq box). The approval of Multaq was based on another trial (ATHENA) in which use of Multaq was associated with a decreased number of deaths compared to placebo.¹

對永久性心房顫動(permanent AF)患者，會提高發生嚴重心血管不良事件(含死亡)之風險。

* 資料來源: <http://www.fda.gov/Safety/MedWatch/SafeInformation>

Multaq (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events

[Updated 12/19/2011]

FDA 完成一項 Multaq (dronedarone) 安全性審查。這項審查說明 Multaq 會增加嚴重心血管疾病的風險，有永久性心房顫動(permanent atrial fibrillation)患者使用 Multaq 甚至會增加死亡的風險。這項審查引用的文獻來自於兩個臨床試驗：PALLAS 和 ATHENA。針對 Multaq 增加心血管疾病的風險，FDA 提供新的建議；Multaq 的仿單也修訂了使用建議：

- 有永久性心房顫動(permanent atrial fibrillation)的患者不應使用 Multaq，因為 Multaq 會增加這類患者的心血管疾病的死亡率，和中風、心衰竭的發生率。
- 使用 Multaq 時，至少每三個月使用心電圖監測心律。若有心房顫動發生，應立即停藥；若臨床需要，應治療患者的心律不整。
- Multaq 用於降低非永久性心房顫動(non-permanent AF, paroxysmal or persistent AF)的患者的住院率。
- 患者使用 Multaq 時，應接受適當的抗血栓治療。

食品藥物管理局說明Dronedarone成分藥品之用藥安全資訊

歐洲醫藥管理局（EMA）近日發布含 dronedarone成分藥品之用藥安全資訊，根據臨床試驗（PALLAS study）研究及2011年該藥品之總體性臨床效益與風險評估報告，顯示使用含該成分藥品可能導致嚴重肝臟傷害及嚴重心臟血管副作用，同時亦可能造成肺部傷害之風險，因此重新規範使用該藥品，同時將持續追蹤該藥品之安全性。

經查，衛生署於99年6月核准含 dronedarone成分藥品，中文品名為「脈泰克膜衣錠」，英文品名為「Multaq」，作為治療心律不整之用途。該藥品許可證持有廠商，已向衛生署申請仿單更新，最新版之仿單中已加刊相關警語、注意事項，並要求該藥品僅侷限用於病人有陣發性或持續性心房纖維顫動(AF)，且目前處於竇性節律（sinus rhythm）狀態，並需經專科醫師評估無更適當之抗心律不整藥品可供選擇情況下，始可使用。Dronedarone不可用於永久性心房纖維顫動、心臟衰竭、已有肝或肺傷害且已接受Aminodarone或另一種抗心律不整藥品之病人。服用該藥品之病人應定期監視心律及肺、肝功能；初期治療之數週，尤其應密切監視病人之肝功能。衛生署食品藥物管理局提醒正在使用該藥品之病患，勿擅自停藥，若有任何疑慮或不適，應立即回診詢問主治醫師。


食品藥物管理局已建立藥物安全資訊主動監控機制，除有藥物不良反應通報系統之外，對於安全有關訊息，隨時進行瞭解，以保障民眾之用藥安全，若該藥品導致不良反應發生時，請立即通報給衛生署所建置藥物不良反應通報專線02-2396-0100，網站：<http://adr.doh.gov.tw>。

應持續追蹤該藥品之安全性!!

* 資料來源：行政院衛生署食品藥物管理局 <http://www.doh.gov.tw>

上市後藥品風險控制

▶ 採取措施



▶ 行政院衛生署食品藥管理局於2012/1/3 (二) 發佈安全警訊

aliskiren (Rasilez®) 之用藥資訊 (發布日期2012-01-03)

歐洲醫藥管理局(EMA)於最近發布新聞指出，治療高血壓藥品aliskiren (藥品名稱Rasilez®) 之藥品許可證持有廠商決定終止一項「aliskiren成分藥品新適應症之臨床試驗」，該新適應症之臨床試驗嘗試加入aliskiren於已服用血管收縮素轉化酶抑制劑(ACEI)或血管收縮素受體阻斷劑(ARB)的第二型糖尿病患者，且同時併有腎功能不全或有重大心血管疾病病史之高危險群病人，評估是否可以降低心血管疾病與腎臟疾病的發生率及致死率。其初步結果顯示該項臨床試驗無法提高臨床效益，卻可能會增加非致死性中風、高血鉀、低血壓、腎臟併發症等風險，因此該藥廠決定終止此「新適應症之臨床試驗」。

食品藥物管理局為保障民眾用藥安全，已同步停止國內參與該項新適應症之臨床試驗計畫，並請藥廠儘速提供該臨床試驗計畫報告及相關安全資訊，食品藥物管理局將儘速評估其整體風險與臨床效益。

衛生署自97年9月10日核准含aliskiren成分藥品許可證，目前含該成分藥品許可證共6張，核可之適應症為「治療高血壓」，均為安全監視期之藥品，藥商必須定期提報國內、外定期安全性報告至食品藥物管理局，以利隨時了解其臨床使用情形。經查，全國藥物不良反應通報資料，目前僅有1件非嚴重不良反應通報案例。在衛生署未有進一步評估結果之前，食品藥物管理局建議醫師宜立即檢視正在使用aliskiren的糖尿病患者，如果同時併用血管收縮素轉化酶抑制劑或血管收縮素受體阻斷劑，宜停用aliskiren，並監視病人不良反應情形。服用該成分藥品之糖尿病患者，不可擅自停藥，應回診開立處方之主治醫師。

食品藥物管理局已建立藥物安全資訊主動監控機制，除有藥物不良反應通報系統之外，對於安全有關訊息，隨時進行瞭解，以保障民眾之用藥安全，提醒醫療人員或病患懷疑因為使用(服用)藥品導致不良反應發生時，請立即通報給衛生署所建置之全國藥物不良反應通報中心，藥物不良反應通報專線02-2396-0100，網站：<http://adr.doh.gov.tw>。

*資料來源: 行政院衛生署食品藥管理局 <http://goo.gl/gYCM0>

藥物資訊查詢

_Dronedarone藥品使用評估



何處找資料？

► 背景問題 (background question)

- Dose, indication, monitor, ... **MICROMEDEX® 2.0**

► 前景問題 (foreground question)

- 目前是否有相似的研究？
- 療效/風險/效益



Key關鍵字→ dronedarone→ 349篇

NCBI Resources ☒ How To ☒ ed100645 My NCBI Sign Out

PubMed.gov US National Library of Medicine National Institutes of Health

PubMed

Help

[Choose additional filters](#)

Text availability
Abstract available
Free full text available
Full text available

Publication dates
5 years
10 years
Custom range...

Species
Humans
Other Animals

Article types
Clinical Trial
Meta-Analysis
Practice Guideline
Randomized Controlled

Display Settings: ☒ Summary, 20 per page, Sorted by Recently Added **Send to:**

Results: 1 to 20 of 349 << First < Prev Page of 18 Next > Last >

☐ [Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spontaneous Adverse Event Reporting.](#)
Kao DP, Hiatt WR, Krantz MJ.
Pharmacotherapy. 2012 Jun 28. doi: 10.1002/j.1875-9114.2012.01118.x. [Epub ahead of print]
PMID: 22744806 [PubMed - as supplied by publisher] [Related citations](#)

☐ [Addressing the management of atrial fibrillation - a systematic review of the role of dronedarone.](#)
Podda GM, Casazza G, Casella F, Dipaola F, Scannella E, Tagliabue L.
Int J Gen Med. 2012;5:465-78. Epub 2012 May 28.
PMID: 22701087 [PubMed - in process] **Free PMC Article** [Related citations](#)

☐ [\[Rhythm---control in atrial fibrillation\].](#)
Lewalter T.
MMW Fortschr Med. 2012 Mar 22;154(5):55-7. German. No abstract available.
PMID: 22624266 [PubMed - indexed for MEDLINE] [Related citations](#)

Filter your results:

All (349)

[Clinical Trial \(19\)](#)

[Meta-analysis \(4\)](#)

[Practice Guideline \(2\)](#)

[Published in the last 5 years \(269\)](#)

[Randomized Controlled Trial \(17\)](#)

[Review \(125\)](#)

[Systematic Reviews \(26\)](#)

[Therapy/Broad \(274\)](#)

[systematic review \(20\)](#)

[Therapy \(270\)](#)

[Diagnosis \(144\)](#)

[Economics \(6\)](#)

[Manage Filters](#)

Dronedarone 藥品使用評估

“Drug Utilization **Evaluation**” OR “Drug Utilization **Review**”

NCBI Resources How To My NCBI Sign In

PubMed.gov US National Library of Medicine National Institutes of Health

PubMed ("drug utilization evaluation[MeSH]) " OR "drug utilization review"[MeSH]) AND dronedarone Search

RSS Save search Advanced Help

Display Settings: Abstract Send to: ELSEVIER FULL-TEXT ARTICLE

Only 1 article found. Search details.

Clin Ther. 2011 Oct;33(10):1483-1490.e3. Epub 2011 Sep 29.

Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.

Gao S, Juhaeri J, Schiappacasse HA, Koren AT, Dai WS.

Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, New Jersey, USA. shujun.gao@sanofi-pasteur.com

Abstract

BACKGROUND: The utilization pattern of dronedarone was unknown, especially regarding prescribers' compliance with the product's prescribing information (PI) following its availability and the implementation of the Food and Drug Administration-approved risk evaluation and mitigation strategy for the drug in the United States.

OBJECTIVE: This study was designed to evaluate the dronedarone prescribers' adherence to PI regarding the following contraindications: (1) patients with heart failure (HF) with a recent decompensation requiring hospitalization or referral to a specialist, (2) concomitant use of potent CYP3A4 inhibitors, and (3) concomitant use of QT-prolonging drugs.

METHODS: Patients prescribed dronedarone between July 2009 and August 2010 were identified through LabRx. The following rates surrounding dronedarone use were examined: (1) atrial fibrillation or atrial flutter in the past year, (2) worsening or hospitalization for HF within the month before prescription, and (3) concomitant prescription of potent CYP3A4 inhibitors and concomitant prescription of QT-prolonging drugs within the following month.

RESULTS: A total of 4595 dronedarone prescriptions were filled by 1820 patients. More than 94% of the participants had ≥1 diagnosis of atrial fibrillation or atrial flutter in the previous year. Worsening of or hospitalization for HF was found in 61 (3.4%) patients within the month before receiving dronedarone, including 18 patients with HF as the primary cause for hospitalization. Potent CYP3A4 inhibitors were prescribed to 10 (0.6%) patients within a month following dronedarone initiation, 6 of whom received them for topical use only. QT-prolonging drugs were prescribed to 67 (3.7%) patients within a month following dronedarone initiation, among which >90% were other antiarrhythmics.

Save items Add to Favorites

Related citations in PubMed

Review Dronedarone for the treatment of atrial fibrillation and atria [Health Technol Assess. 2010]

Review Dronedarone for the treatment of atrial fibrillation and atria [Vasc Health Risk Manag. 2010]

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel [Circulation. 2009]

Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients [Clin Cardiol. 2010]

Dronedarone in high-risk permanent atrial fibrillation. [N Engl J Med. 2011]

See reviews... See all...

Related information

Related Citations

Compound (MeSH Keyword)

Substance (MeSH Keyword)

Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database

Shujun Gao, MD, MPH, PhD¹; Juhaeri Juhaeri, PhD¹; Heather A. Schiappacasse, PharmD, MBA²; Andrew T. Koren, MD³; and Wanju S. Dai, MD¹

¹Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, New Jersey; ²US Risk Identification, Surveillance and Communication, Sanofi, Bridgewater, New Jersey; and ³US Medical Affairs, Sanofi, Bridgewater, New Jersey

ABSTRACT

Background: Dronedarone was unknown to the Food and Drug Administration and its safety profile was unknown.

Objective: This study was designed to evaluate the dronedarone prescribers' adherence to PI regarding the following contraindications: (1) patients with heart failure (HF) with a recent decompensation requiring hospitalization or referral to a specialist, (2) concomitant use of potent CYP3A4 inhibitors, and (3) concomitant use of QT-prolonging drugs.

Method: Data were obtained from a large, national, de-identified claims database.

假如只鍵入diabetes mellitus

NCBI Resources ▾ How To ▾

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed ▾ diabetes mellitus

Advanced

Search Details


Query Translation:

```
"diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields]  
AND "mellitus"[All Fields]) OR "diabetes mellitus"[All  
Fields]
```

Search | URI



的索引|名詞 - MeSH名詞



語法

功能

MeSH名詞 **【MeSH】** 搜尋標有該MeSH名詞的文章

MeSH名詞主題 **【Mejr】** 搜尋以該MeSH名詞為主題的文章

★ PubMed已經可以同時以自然語言及MeSH進行搜尋

★ 要限定只搜尋特定MeSH名詞，可鍵入” “drug
utilization evaluation” **【 MeSH 】**

My NCBI 個人化服務

- ▶點選右上角之” My NCBI”
- ▶登入個人帳號密碼

NCBI Resources ▾ How To ▾ My NCBI Sign In

My NCBI

My NCBI Overview

My NCBI allows you to create automatic email alerts, save your searches and records, filter results by subject, and *much more*.

PDA login users: The PDA (Primary Data Archives) authentication system has merged with My NCBI. Please login via My NCBI using your existing PDA username and password.

Sign in directly to your My NCBI account:

Register or sign in through one of the partner organization login routes:

My NCBI Sign In

Username:

Password:

☐ Keep me signed in unless I sign out
(Leave unchecked on public computers)

☒ Remember my username

[Register for an account](#)

Sign in via Partner Organization

- [Google](#)
- [NIH & eRA Commons](#)
- [UKPMC Funders Group grantees](#)


Or choose from:

Brown University
Case Western Reserve University
Colorado State University
Columbia University

▲
▼

[See expanded list »](#)

MyNCBI 個人化服務



設定個人喜愛的過濾器 (filters)

Search NCBI databases

Search: PubMed [v]

Hint: clicking the "Search" button without any term will transport you to that database's homepage.

My Bibliography

Your bibliography contains

Use the "Send to > My Bibliography" menu OR
Click here to manually create

Recent Activity

Active	Name	Type
☒	Therapy	Custom
☒	Diagnosis	Custom
☒	Economics	Custom
☒	Systematic Review	Custom
☒	Clinical Trial	Standard filter
☒	Meta-analysis	Standard filter
☒	Practice Guideline	Standard filter
☒	Published in the last 5 years	Standard filter
☒	Randomized Controlled Trial	Standard filter
☒	Review	Standard filter
☒	Therapy/Broad	Standard filter

Filters for: PubMed (11 active) [v]

[Manage Filters »](#)

勾選 "Active" 選項來確認是否要啟動

編輯filters

NCBI Resources How To

ed100645 My NCBI

My NCBI — Filters

You are managing filters for: PubMed

Choose another database: PubMed (11 active)

Your PubMed filter list

Create custom filter

Active	Name	Type	
☒	Therapy	Custom	delete
☒	Diagnosis	Custom	delete
☒	Economics	Custom	delete
☒	Systematic Review	Custom	delete
☒	Clinical Trial	Standard filter	
☒	Meta-analysis	Standard filter	
☒	Practice Guideline	Standard filter	
☒	Published in the last 5 years	Standard filter	
☒	Randomized Controlled Trial	Standard filter	
☒	Review	Standard filter	
☒	Therapy/Broad		

Browse/Search for PubMed Filters

Select category:

☒ Popular ☐ LinkOut ☐ Properties ☐ Links

Search with terms (optional):

Search

Active	Name	Description
☒	Clinical Trial	
☐	English	
☐	English & Humans	
☐	Free Full Text	links to Web accessible full text articles (all available free of charge)
☐	Full Text	links to Web accessible full text articles (some require subscription)

我個人設定好的filters

Filter分類篩選設定

NCBI Resources How To ed100645 My NCBI Sign Out

My NCBI — Filters

You are managing filters

Your PubMed filter list

Active	Name	Type
☒	Therapy	Custom
☒	Diagnosis	Custom
☒	Economics	Custom
☒	Systematic Review	Custom

Create

鍵入欲執行檢索的條件/語法

1

2

測試語法的檢索筆數

Test This Query

(See number of results for this query.)

3

按儲存

Save Filter

Free Full Text links to Web accessible full text articles (all available free of charge)

Full Text links to Web accessible full text articles (some may require subscription)

Humans

((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])

臨床文獻最佳化篩選介面

Clinical Queries

NCBI Resources ☒ How To ☒ ed100

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed

Advanced



PubMed

PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Using PubMed

[PubMed Quick Start Guide](#)

[Full Text Articles](#)

[PubMed FAQs](#)

[PubMed Tutorials](#)

[New and Noteworthy](#) 

PubMed Tools

[PubMed Mobile](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[Topic Specific Queries](#)

More Resources

[MeSH Database](#)

[Journals in NCBI Databases](#)

[Clinical Trials](#)

[E-Utilities](#)

[LinkOut](#)

Clinical Study Categories -Research Methodology Filters

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use [PubMed](#) directly.

臨床研究最佳化篩選

Clinical Study Categories

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by [Haynes RB et al.](#) See more [filter information](#).

Systematic Reviews

This column displays citations for systematic reviews, meta-analyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See [filter information](#) or additional [related sources](#).

Medical Genetics

This column displays citations pertaining to topics in medical genetics. See more [filter information](#).

Filter info

Clinical Queries using Research Methodology Filters

Category	Optimized For	Sensitive/ Specific	PubMed Equivalent
therapy	sensitive/broad	99%/70%	((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])
	specific/narrow	93%/97%	(randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]))
diagnosis	sensitive/broad	98%/74%	(sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] OR diagnosis,differential[MeSH:noexp] OR diagnosis[Subheading:noexp])
	specific/narrow	64%/98%	(specificity[Title/Abstract])
etiology	sensitive/broad	93%/63%	(risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk * [MeSH:noexp] OR cohort studies [MeSH Terms] OR group*[Text Word])
	specific/narrow	51%/95%	((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract]))
prognosis	sensitive/broad	90%/80%	(incidence[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies [MeSH:noexp] OR prognos*[Text Word] OR predict*[Text Word] OR course*[Text Word])
	specific/narrow	52%/94%	(prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract])
clinical prediction guides	sensitive/broad	96%/79%	(predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])
	specific/narrow	54%/99%	(validation[tiab] OR validate[tiab])

Filter分類篩選設定

NCBI Resources How To ed100645 My NCBI Sign Out

My NCBI — Filters

You are managing filters

Your PubMed filter list

Active	Name	Type
☒	Therapy	Custom
☒	Diagnosis	Custom
☒	Economics	Custom
☒	Systematic Review	Custom

Create

鍵入欲執行檢索的條件/語法

1

2

測試語法的檢索筆數

Test This Query

(See number of results for this query.)

3

命名/按儲存

Save Filter

Free Full Text links to Web accessible full text articles (all available free of charge)

Full Text links to Web accessible full text articles (some may require subscription)

Humans

((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])

You are managing filters for: PubMed C

Your PubMed filter list

Create custom filter

Active	Name	Type	
☒	Therapy 	Custom	delete
☒	Diagnosis 	Custom	delete
☒	Economics 	Custom	delete
☒	Systematic Review 	Custom	delete
☒	Clinical Queries-therapy narrow 	Custom	delete
☒	Clinical Trial	Standard filter	
☒	Meta-analysis	Standard filter	
☒	Practice Guideline	Standard filter	
☒	Published in the last 5 years	Standard filter	
☒	Randomized Controlled Trial	Standard filter	
☒	Review	Standard filter	
☒	Therapy/Broad	Standard filter	

PubMed Dronedarone

RSS Save search Advanced

[Choose additional filters](#)

Text availability

Abstract available

Free full text available

Full text available

Publication dates

5 years

10 years

Custom range...

Species

Humans

Other Animals

Article types

Clinical Trial

Meta-Analysis

Practice Guideline

Randomized Controlled Trial

Review

Systematic Reviews

more ...

Languages

English

more ...

Display Settings: ☒ Summary, 20 per page, Sorted by Recently Added

Results: 1 to 20 of 352

<< First < Prev

☐ [Efficacy and safety profile of dronedarone in clinical practice. Results of](#)

1. [Registry \(MADRE study\).](#)

Said SM, Esperer HD, Kluba K, Genz C, Wiedemann AK, Boenigk H, Herold
Dullaues RC.

Int J Cardiol. 2012 Jul 9. [Epub ahead of print]

PMID: 22781508 [PubMed - as supplied by publisher]

[Related citations](#)

☐ [Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada](#)

2. [Switzerland.](#)

Akerborg O, Nilsson J, Bascle S, Lindgren P, Reynolds M.

Clin Ther. 2012 Jul 5. [Epub ahead of print]

PMID: 22770643 [PubMed - as supplied by publisher]

[Related citations](#)

☐ [Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spontaneous](#)

3. [Reporting.](#)

Kao DP, Hiatt WR, Krantz MJ.

Pharmacotherapy. 2012 Jun 28. doi: 10.1002/j.1875-9114.2012.01118.x. [Epub ahead of print]

PMID: 22744806 [PubMed - as supplied by publisher]

[Related citations](#)

☐ [Addressing the management of atrial fibrillation - a systematic review of the role of dronedarone.](#)

4. [Bodda GM, Casazza G, Casella E, Dinola E, Scannella E, Taddei L](#)

dronedarone in high risk permanent atrial
fibrillation

Filter your results:

All (352)

[Clinical Trial \(19\)](#)

[Practice Guideline \(3\)](#)

[Published in the last 5 years \(272\)](#)

[Randomized Controlled Trial \(17\)](#)

[Review \(126\)](#)

[Therapy/Broad \(275\)](#)

[Therapy \(273\)](#)

[Diagnosis \(144\)](#)

[Economics \(7\)](#)

[Systematic Review \(129\)](#)

[Clinical Queries-therapy narrow \(23\)](#)

Search NCBI databases

Search : PubMed

Search

Hint: clicking the "Search" button without any terms listed in the search box will transport you to that database's homepage.

Saved Searches

Search Name

PubMed Searches

((oligospermia OR male infertility OR (Male
[MeS...

喜好設定

Common Preferences

Username	ed100645
Password	*****
E-mail Address	melody_0320@hotmail.com (confirmed)
Links Display	Popup Menu
Highlighting	Yellow
Shared Settings	None
Linked Account	None

關鍵字以顏色標

PubMed Preferences

Abstract Supplemental Data	Closed
Document Delivery	None Selected
PubMed Filters & Icons	Clinical Trial, Practice Guideline, Published in the J, Therapy, Diagnosis, Economics, Systematic Review
Outside Tool	None Selected
Auto Suggest	On
Result Display Settings	Summary, 20, Recently Added

Many of NCBI's databases can use color to highlight the search results.

- ☐ None
- ☐ Bold
- ☐ Light Yellow
- ☐ Green
- ☐ Purple
- ☐ Aqua
- ☐ Gold
- ☒ Yellow
- ☐ Sky Blue
- ☐ Lime Green
- ☐ Hot Pink
- ☐ Red

Save

Or cancel and return to the preferences page

藥物資訊查詢 _替代藥品



病患罹患心律不整又合併心衰竭時，
該如何選擇？

MICROMEDEX® 2.0





關鍵字

antiarrhythmic, heart failure

Atrial fibrillation in patients with heart failure

New Search Patient

Search Results for "atrial fibrillation in patients with heart failure"

☒ All Topics

☐ Adult

☐ Pediatric

☐ Patient

☐ Graphics

- Atrial fibrillation in patients with heart failure**
- Antiarrhythmic drugs to maintain sinus rhythm: Recommendations
- Antiarrhythmic drugs to maintain sinus rhythm: trials
- Secondary and primary prevention of sudden cardiac death in patients with heart failure
- Drugs that should be avoided or used with caution in patients with heart failure
- Role of antiarrhythmic drugs for ventricular arrhythmias after myocardial infarction
- Evaluation of the patient with heart failure and atrial fibrillation
- Ventricular arrhythmias in heart failure and the role of antiarrhythmic drugs
- Treatment of acute decompensated heart failure with atrial fibrillation
- Overview of the therapy of heart failure due to atrial fibrillation
- Therapeutic use and major side effects of sotalol
- Clinical uses of amiodarone
- Treatment and prognosis of myocarditis in patients with heart failure
- Therapeutic use of ibutilide

Topic Outline

- INTRODUCTION
- INCIDENCE AND PREVALENCE
- EFFECT ON CARDIAC FUNCTION
- PROGNOSIS
- GENERAL MANAGEMENT ISSUES
- RHYTHM VERSUS RATE CONTROL
- RATE CONTROL**
 - Rate-control goal
 - Patients with preserved left ventricular systolic function
 - AV node ablation with pacing
- RHYTHM CONTROL**
 - Cardioversion
 - Antiarrhythmic drug therapy
 - Amiodarone
 - Dofetilide
 - Dronedarone
 - Sotalol
 - Class IC drugs
 - Possible role of beta blockers
 - Possible role of angiotensin inhibition
 - Pulmonary vein isolation


基本藥物資訊查詢 _交互作用



Tamoxifen與Warfarin是否可以併用？

遇到交互作用問題，該怎麼做呢？

- ▶ 衛生署藥品交互作用資料庫 (關閉中)
- ▶ **Drug Interaction Facts**
- ▶ **MICROMEDEX® 2.0**



院內交互作用查詢系統



一、依藥品組合查詢：

步驟1. 請拉選查詢藥品: (學名)

步驟2. 請拉選比對藥品: (學名)

*若選擇All則對所有藥品進行比對


步驟3. 查詢結果: 6筆

二、依查詢藥品名稱字首查詢：[A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

查詢藥品 名稱	比對藥品 名稱	影響 等級	Onset	Severity	Documentation	Effects	
Tamoxifen 10mg/tab	Rifabutin 150mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 150mg+Isoniazide 100mg (Rifinah)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 150mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 300mg + Isoniazide 150mg (Rifinah)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin(RIF) 300mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin+INAH+PZA(Rifater)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN

➤ Tamoxifen與Warfarin併用安全嗎？

Drug Interaction Facts



David S. Tatro, PharmD

Drug Interaction Facts™

THE AUTHORITY ON DRUG INTERACTIONS

2012



Facts & Comparisons®

Anticoagulants		Tamoxifen	
Warfarin* (eg, Coumadin)		Tamoxifen*	
Significance	Onset ☐ Rapid ☒ Delayed	Severity ☒ Major ☐ Moderate ☐ Minor	Documentation ☐ Established ☐ Probable ☒ Suspected ☐ Possible ☐ Unlikely
1			
Effects	The hypoprothrombinemic effect of oral ANTICOAGULANTS may be increased, possibly with bleeding.		
Mechanism	Unknown.		
Management	If an interaction is suspected, consider decreasing the dose of oral ANTICOAGULANTS during coadministration of TAMOXIFEN. Monitor PT and adjust the dose accordingly.		

Warfarin

延遲

嚴重

可疑



2 Venlafaxine, 1772

4 Warfarin, 182

Tamsulosin,

2 Ethanol, 40

2 Tadalafil, 43

2 Vardenafil, 1979

勘誤!!

工具: [藥物相互作用](#) | [Missel's™2 IV 相容性](#) | [藥物鑒定](#) | [Tox 和藥物產品查找](#) | [藥物比較](#) | [計算器](#) | [CareNotes®](#)

藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 ►（新增）按鈕。

輸入搜尋
詞:

相符的藥物名稱: (3)

- Warfarin
- Warfarin Sod
- Warfarin Sodium

要檢查的藥物:

[Add Allergies ►](#)

Tamoxifen Citrate
Warfarin

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

Drug Interaction Results

[← 修改相互作用](#)

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： [藥物-藥物 \(1\)](#) | [複方 \(0\)](#) | [過敏症狀 \(0\)](#) | [食物 \(6\)](#) | [乙醇 \(1\)](#) | [實驗室 \(0\)](#) | [抽煙 \(1\)](#) | [懷孕 \(2\)](#) | [哺乳期 \(2\)](#)

Drug-Drug 相互作用 (1)

藥物：

嚴重性：

文件：

綜述：

TAMOXIFEN CITRATE [Systemic] – WARFARIN SODIUM [Systemic] [Warfarin]



Contraindicated

Good

Concurrent use of TAMOXIFEN and WARFARIN may result in an increased risk of bleeding.

強烈建議相互作用的存在

複方 (未找到)

Drug-過敏症狀 相互作用 (未找到)

Drug-食物 相互作用 (6)

藥物：

嚴重性：

文件：

綜述：

WARFARIN SODIUM [Systemic] [Warfarin]



Major

Good

Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.

WARFARIN SODIUM [Systemic] [Warfarin]



Major

Good

Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.



細化方式： 藥物： All

跳轉到： 藥物-藥物 (

(2)

Drug-Drug 相互作用

藥物：

TAMOXIFEN CITRATE [S
[Systemic] [Warfarin]

d WAR

複方 (未找到)

Drug-過敏症狀 相互

Drug-食物 相互作用

藥物：

WARFARIN SODIUM [Sy

INTERACTION DETAIL

Warning:

可能增加病患出血的風險

Concurrent use of TAMOXIFEN and WARFARIN may result in an increased risk of bleeding.

Clinical Management:

Concurrent administration of tamoxifen and coumarin-type anticoagulants, including warfarin, is contraindicated in high-risk women and women with ductal carcinoma in situ where tamoxifen is used to reduce the incidence of breast cancer. In other clinical situations where tamoxifen is used concurrently with warfarin, consider using lower warfarin doses and closely monitor the INR (international normalized ratio) with the addition and withdrawal of treatment with tamoxifen and periodically.

Onset:

Delayed

Severity:

Contraindicated

Documentation:

**1.考慮使用較低的劑量
2.密切監測INR值**

列印 關閉 X

WARFARIN SODIUM [Systemic] [Warfarin]

S Major

Good

Concurrent use of WARFARIN and CRAN
may result in an increased risk of bleedin

查詢多重藥品交互作用...

藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 ►（新增）按鈕。

輸入搜尋

詞:

可鍵入多種藥品一併作完整的比對

相符的藥物名稱: (3)

Warfarin
Warfarin Sod
Warfarin Sodium

要檢查的藥物：

Add Allergies ►

Losartan Potassium
Metformin Hydrochloride
Tamoxifen Citrate
Warfarin

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

Drug Interaction Results

修改相互作用

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物-藥物 (1) | 複方 (0) | 過敏症狀 (0) | 食物 (7) | 乙醇 (2) | 實驗室 (0) | 抽煙 (1) | 懷孕 (4) | 哺乳期 (4)


Drug-過敏症狀 相互作用（未找到）

Drug-食物 相互作用 (7)



藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM [Systemic] [Warfarin]	 Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM [Systemic] [Warfarin]	 Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.
WARFARIN SODIUM [Oral (systemic)] [Warfarin]	 Moderate	Good	Concurrent use of WARFARIN and ENTERAL NUTRITION may result in decreased PT/INR response to warfarin and development of warfarin resistance.
WARFARIN SODIUM [Systemic] [Warfarin]	 Moderate	Good	Concurrent use of WARFARIN and NONI JUICE may result in risk of acquiring warfarin resistance.
WARFARIN SODIUM [Systemic] [Warfarin]	 Moderate	Good	Concurrent use of WARFARIN and HIGH-PROTEIN DIET may result in reduced warfarin anticoagulant effectiveness.
WARFARIN SODIUM [Systemic] [Warfarin]	 Moderate	Excellent	Concurrent use of WARFARIN and VITAMIN K FOODS may result in altered anticoagulant effectiveness.
LOSARTAN POTASSIUM [Systemic]	 Minor	Good	Concurrent use of LOSARTAN and GRAPEFRUIT JUICE may result in increased half-life (t1/2) and decreased area under the concentration time curve (AUC) of losartan's active metabolite (E3174).

MICROMEDEX® 2.0



- ▶ Mobile website: all devices
- ▶ Comprehensive drug information
- ▶ Access at the bedside (point of care)
- ▶ NO FEE



Medical App: Micromedex Drug Information



Medical App: Micromedex Drug Information



展開後的內容

Thank you!

Evidence Based Health Care





Invitation

2012台灣臨床藥學年會

時間：2012.11.04 星期日

地點：高雄義大皇冠假日飯店



社團法人台灣臨床藥學會

誠摯邀請您